Blood cancers have seen tremendous advancements in the past few years owing to the dedication of the researchers who are putting their endless efforts just to bring innovation into the lives of suffering patients. These experimentations and their upshots are always brought to us through various platforms, the American Society of Hematology (ASH) being one of them. This content includes the future uptake and competitive landscape of ADCs in DLBCL.
Over the past couple of decades, antibody-drug conjugates have revolutionized the field of oncology. ADCs are composed of 3 parts: an antibody drug, a cytotoxic payload, and a chemical linker protein to hold the 2 parts to...
